# Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease

> **NCT02176187** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 3 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Berodual® Respimat® inhaler
- **DRUG:** Berodual® metered dose inhaler

## Key facts

- **NCT ID:** NCT02176187
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-04
- **Primary completion:** 2004-12
- **Final completion:** —
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02176187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02176187, "Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02176187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*